- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Subfoveal choroidal neovascularisation (CNV) due to pathologic myopia (PM)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 422.2KB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 83.4KB)
Aflibercept – November 2025
Aflibercept: Solution for intravitreal injection 2 mg in 50 microlitres (40 mg per mL) Solution for intravitreal injection 2 mg in 50 microlitres (40 mg per mL) pre‑filled syringe; Eydenzelt® - November 2025
Last updated
5 November 2025